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INTRODUCTION
Radioembolization with Yttrium-90 ( 90 Y) is a liver-directed cancer treatment which has been shown to be effective and prolong overall survival in patients with irresectable primary or metastatic liver cancer [1] [2] [3] [4] [5] [6] . 90 Y-Radioembolization ( 90 Y-RE) is being increasingly used over the last couple of years, since studies have shown that it significantly prolongs time-to-progression compared to transarterial chemoembolization in patients with hepatocellular cancer (HCC) for example, while simultaneously resulting in less toxicity [7, 8] . In general, side effects after 90 Y-RE are uncommon and mostly include mild post-interventional symptoms such as fatigue, abdominal pain, nausea and vomiting [9, 10] . A rare, but serious complication however is non-target embolization of 90 Y particles to the GI tract, which may lead to radiationinduced gastrointestinal ulceration and is thus associated with significant morbidity and mortality [11] . Non-target embolization of the GI tract during 90 Y-RE may result either from hepatoenteric vessels distal to the position of the catheter tip during delivery of the 90 Y microspheres, or from reflux of particles into enteric branches proximal to the location of the catheter tip. A pre-treatment mapping angiogram to assess the hepatic arterial anatomy and embolization of any hepatoenteric vessels deemed to pose a risk for non-target embolization using coils, plugs or glue is therefore routinely performed before radioembolization [12, 13] . Additionally, the catheter is usually placed as distally as possible during delivery of the 90 Y microspheres to minimize the risk of reflux into enteric branches.
However, patients with a variant arterial supply of the liver, such as hepatic arteries originating from the left gastric artery (LGA) or the superior mesenteric artery (SMA) for example, may have an increased risk of non-target embolization due to the close proximity between hepatic and enteric vessel branches.
Therefore, the purpose of this study is to evaluate whether 90 Y-RE with resin microspheres can be safely performed via a replaced right or left hepatic artery (LHA) originating from the SMA or LGA.
MATERIALS AND METHODS
This single-center retrospective study was approved by the institutional review board (IRB, internal reference no. EK 308/18).
Patients
Computed tomography (CT) angiographies and fluoroscopic angiograms of all patients that had undergone radioembolization with 90 Y-resin microspheres (SIRSpheres, Sirtex Medical Ltd, Lane Cove, Australia) between 2010 and 2018 at our institution were retrospectively reviewed and screened for a variant hepatic arterial anatomy. All patients in whom a 90 Y-RE was performed via a replaced right or LHA and with a minimum follow-up of one month were included in this retrospective analysis.
In general, the indication for 90 Y-RE included HCC (BCLC Stage C) and liver-only or liver-dominant metastatic disease of different primary tumors (Table 1 for further details on patient characteristics). All treatment decisions were established by consensus in a multidisciplinary tumor board attended by hepatobiliary surgeons, oncologists, radiotherapists, pathologists and interventional radiologists.
Pre-treatment mapping angiogram
Written informed consent was obtained from all patients before the procedure. All procedures were performed by interventional radiologists with at least 5 years of experience in transarterial oncologic procedures.
As part of the routine work-up before 90 Y-RE, a standard mapping angiogram of the celiac axis, superior mesenteric and hepatic arterial vessels was obtained in all patients several days prior to the actual 90 Y-RE to assess the hepatic vascular anatomy and identify any hepatoenteric vessels deemed at risk for non-target embolization to the GI tract. Wherever possible, these hepatoenteric vessels, e.g., a right phrenic artery arising from an aberrant left hepatic artery, were subsequently embolized using coils.
The microcatheter was then advanced as distally as possible into the respective hepatic artery to a location that was considered appropriate for subsequent delivery of the 90 Y particles. At this location, an arterial phase cone beam CT (Artis Zee or ZeeGo, Siemens Healthcare, Forchheim, Germany) with undiluted contrast agent (Ultravist ® -300, Bayer, Leverkusen, Germany) an injection rate of 0.8-1 mL/s with a total volume of 6.4-8 mL and an injection timing delay of 8 s was performed to screen for possible extrahepatic contrast enhancement. If no extrahepatic enhancement was seen, technetium-99m-labeled macroaggregated albumin ( 99m Tc MAA) was injected and the patient was subsequently transferred to the Department of Nuclear Medicine for a 99m Tc MAA-singe-photon emission CT/CT ( 99m Tc-SPECT/CT) scan to determine the lung shunt fraction and to screen for the presence of extrahepatic activity.
Y-Radioembolization
For the eventual treatment, the tip of the microcatheter was placed at an identical position as during the 99m Tc MAA-test-injection and again a cone beam CT was performed with injection of contrast material through the microcatheter to screen for possible hepatoenteric arterial communications. In 23 out of the 24 patients, 90 Y-RE was performed in a lobar fashion. One patient received three segmental treatments (segments II, III and IV) via a replaced LHA at one-month intervals due to the fact that he had previously undergone right hepatic lobectomy and was therefore considered to have an increased risk of radiation-induced liver disease. Infusion of the 90 Y microspheres was performed slowly, manually under intermittent fluoroscopy to ensure antegrade blood flow at all times. Complete administration of all of the calculated activity was achieved in all cases.
After completion of the procedure, each patient received post-interventional 90 Y bremsstrahlung images and/or a 90 Y positron emission tomography (PET) to evaluate the 90 Y distribution in the liver as well as to screen for any extrahepatic activity as a result of a possible non-target embolization.
Follow-up
After radioembolization, all patients were routinely admitted to the nuclear medicine ward at our institution for 48 h, where they were closely monitored for any signs of acute toxicity by daily clinical examination and laboratory analysis of complete blood count, liver function tests and metabolic panel. After discharge, all patients resumed a routine schedule for follow-up with clinical examination, laboratory analysis (complete blood count, liver function tests, metabolic panel, tumor markers) and cross-sectional imaging (contrast-enhanced MRI or PET/CT) one month after treatment and then every 2-3 mo thereafter.
Data analysis and assessment of toxicity
The primary outcome variable of this study was presence or absence of clinical or imaging evidence of non-target embolization of 90 Y-microspheres to the GI tract. Therefore, electronic medical records of all patients were reviewed for presence of nausea, vomiting, abdominal pain and fever as symptoms of potential gastrointestinal complications on days 1-3 and 4 wk after 90 Y-RE. These data were graded according to the common terminology criteria for adverse events (CTCAE version 5.0); toxicities of level ≥ 3 were defined as clinically relevant. Additionally, all post-interventional 90 Y bremsstrahlung images and 90 Y-PETs, as well as the 99m Tc MAA-SPECT/CTs and arterial cone beam CTs, were retrospectively reviewed for evidence of extrahepatic/gastrointestinal activity or extrahepatic contrast enhancement.
Since catheter positioning is critical for target or non-target embolization, the distance between the position of the microcatheter tip during the administration of the 90 Y particles and the last enteric side branch was determined using angiographic images, cone-beam CT images and pre-interventional CT angiograms (including maximum-intensity projections and curved multi-planar reconstructions whenever necessary). Continuous variables were summarized using proportions, mean and median.
RESULTS
Out of 158 patients who had been treated by means of 90 Y-RE between 2011 and 2018 at our institution, 24 patients (12 females, 12 males, mean age of 60 ± 10 years) had been treated via an aberrant hepatic artery and were therefore included in this retrospective study. There were 11 patients with an LHA originating from the LGA and 13 patients with a right hepatic artery (RHA) originating from the SMA.
Safety and toxicities
90 Y-RE was successfully performed in all 24 patients. All patients were discharged as Tc MAA-SPECT/CTs along the ventral abdominal wall due to a falciforme artery arising from LHA. This falciforme artery could not be embolized due to its very small caliber, however a previous study has shown that there seems to be no absolute need for prophylactic embolization [14] . 90 Y-RE was subsequently performed and resulted in non-target embolization of minor amounts of 90 Y microspheres along the ventral abdominal wall; the patient remained clinically asymptomatic however.
Catheter positioning
The mean distance between the tip of the microcatheter and the last enteric side branch during administration of the 90 Y-microspheres was 3.2 cm (range: 1.9-5 cm) in patients with an aberrant LHA and 5.0 cm (range: 2.1-7.7 cm) in patients with an aberrant RHA ( Table 1 for a summary of patient demographics and treatment characteristics). None of the arterial cone beam CTs that were performed through the microcatheter in place for treatment showed extrahepatic, gastrointestinal contrast enhancement ( Figure 1A-D) .
DISCUSSION
The hepatic arterial anatomy is highly variable; previous studies have shown that 39-49% of all patients have some form of variant arterial blood supply to the liver [15, 16] . The two most common variants include a replaced RHA originating from the SMA with a reported prevalence of 12%-15%, and a LHA originating from the LGA with a prevalence between 4.5% and 8% [15, 16] . These anatomic variants may complicate treatment by means of 90 Y-RE, because of the close proximity of hepatic and enteric branches, which may increase the risk of non-target embolization of the GI tract through reflux of 90 Y microspheres. This is particularly true for patients with an LHA originating from the LGA, since the distance between the origin of a replaced LHA at the LGA and the first intrahepatic side branch of the LHA is often particularly short.
In our study, the mean distance between catheter position during delivery of the 90 Y particles and the last enteric side branch was shortest in patients with an LHA arising from the LGA, with the minimum distance being 1.9 cm. However, none of the patients developed clinically relevant signs and symptoms of gastrointestinal nontarget embolization during follow-up and there was no evidence of 90 Y activity in the GI tract on the postinterventional 90 Y bremsstrahlung images or PET images in any of the patients. The results of this case series therefore suggest, that 90 Y-RE with resin microspheres can be safely performed via hepatic arteries originating from either the SMA or the LGA.
Of course, the infusion rate of the 90 Y particles can also significantly impact the risk of reflux and thus non-target embolization. Although administration of the 90 Y particles was done manually without recording the infusion rate, we did not observe any reflux of contrast agent on the arterial cone beam CTs during the interventions. These were performed with mechanical infusion of contrast agent at a rate of 0.8-1 mL/s, and this rate could be therefore considered a safe starting point. However, hemodynamics will usually change during the procedure due to an increasing number of small vessels getting occluded by the microspheres and therefore intermittent fluoroscopy to adjust the infusion rate and verify antegrade blood flow at all times is strongly recommended. Alternatively, the use of glass microspheres (Theraspheres, BTG International, Ottawa, Ontario, Canada) instead of resin microspheres may decrease the risk for stasis and reflux of particles during treatment due to the decreased embolic load of glass microspheres compared with resin microspheres.
Several studies have explored the option of coil embolization of variant hepatic arteries before 90 Y-RE as a method to redistribute and simplify the hepatic blood flow [17] [18] [19] . For example, coil embolization of an LHA arising from the LGA may be used to induce redistribution of the intrahepatic arterial blood flow to the left hepatic lobe via collaterals from the RHA and therefore facilitate whole liver treatment from a single treatment position in the RHA. While this technique can be used to avoid a potential non-target embolization to the LGA, it also eliminates the option of a selective lobar treatment in patients with a predominantly left hepatic tumor load. Additionally, due to the irreversibility of the coil embolization, it may limit future selective transarterial treatment options as well as surgical options, should the patient respond extremely well to the treatment and become a surgical candidate.
The main limitations of this study include its retrospective study design and the small patient cohort. As mentioned before, the individual hepatic arterial anatomy is highly variable and so are the number of hepatoenteric vessels and the distance between hepatic and enteric branches, which significantly impacts the risk of nontarget embolization to the GI tract. Therefore, the results of this study may not be applicable to all patients and careful evaluation of the individual arterial anatomy before and during 90 Y-RE is still necessary in all patients. Lastly, gastrointestinal complications after 90 Y-RE are occasionally not diagnosed until several months after treatment [20] . However, this appears to be mostly attributable to misrecognition of the rather unspecific abdominal symptoms, something that appears avoidable when follow-up is performed by specialists who are familiar with these potential postinterventional complications.
In conclusion, 90 Y-RE with resin microspheres via an RHA originating from the SMA and/or a LHA replaced to the LGA appears to be feasible and safe. We did not observe any evidence of non-target embolization in 24 patients with placement of the tip of the microcatheter at least 1.9 cm distal of the last enteric side branch and slow manual infusion of the 90 Y-particles.
ARTICLE HIGHLIGHTS

Research Background
Radioembolization with Yttrium-90 ( 90 Y) microspheres is commonly used for treatment of primary or secondary liver tumors. It is generally a well-tolerated treatment with few side effects, however non-target embolization of 90 Y microspheres to the gastrointestinal tract is a severe potential complication. The risk for non-target embolization is very low in patients with a normal hepatic arterial anatomy. However, around 45% of patients have some form of variant hepatic arterial anatomy and patients with aberrant hepatic arteries might have a higher risk for reflux and non-target embolization of 90 Y microspheres due to the close proximity between hepatic and enteric vessel branches.
Research motivation
So far, no study has specifically evaluated the safety of 90 Y-Radioembolization in patients with a variant hepatic arterial anatomy. Therefore, this study aimed to evaluate whether there is an increased risk for non-target embolization during 90 Y Radioembolization in this specific patient population.
Research objectives
To evaluate the safety of 90 Y Radioembolization with resin microspheres in patients with one of the two most common hepatic arterial variants: A right hepatic artery (RHA) originating from the superior mesenteric artery (SMA) or a left hepatic artery (LHA) originating from the left gastric artery (LGA).
Research methods
For this study, electronic medical records and imaging studies of 24 patients who had been treated with Radioembolization via an aberrant hepatic artery were retrospectively reviewed regarding clinical and imaging evidence of non-target embolization of 90 Y-resin microspheres to the GI tract. 11 patients who underwent 90 Y Radioembolization via an LHA originating from the LGA and 13 patients who underwent 90 Y Radioembolization via an RHA originating from the SMA were included. Positioning of the tip of the microcatheter in relationship to the last hepatoenteric side branch was retrospectively analyzed using angiographic images, cone-beam CT and pre-interventional CT-angiograms.
